Kenvue rebounds after Trump Tylenol claims as analysts see limited legal risk

Core Viewpoint - Kenvue shares experienced a recovery of over 5% in premarket trading after hitting a record low, following comments made by US President Donald Trump regarding the company's popular pain relief product [1] Group 1 - Kenvue's stock price rose more than 5% in premarket trading on Tuesday [1] - The increase in share price comes after the company reached a record low in the previous session [1] - US President Donald Trump's remarks linked to Kenvue's pain relief product contributed to the recovery in stock price [1]